defenseworld.net
ImpediMed Q2 Earnings Call Highlights
ImpediMed (ASX: IPD) outlined progress across its SOZO digital health platform during a quarterly update call, while acknowledging a softer-than-expected U.S. sales quarter for its breast cancer-related lymphedema (BCRL) business. Management said it remains focused on converting a large sales pipeline, expanding reimbursement, and accelerating growth initiatives in heart health and wellness and weight management following